Fertility AI Advantage Pregmune offers IRMA, an AI-driven comprehensive reproductive immunology assessment that analyzes over fifty attributes from patient history, labs, and demographics, presenting a scalable value proposition to fertility clinics seeking data-backed decisions.

Partner Testing Opportunity Some IRMA tests involve both parents or donors, suggesting collaboration opportunities with sperm banks, IVF clinics, and reproductive centers to expand testing scope and drive joint offerings.

Early Market Entry With a recent launch of IRMA and a lean team, there is potential to partner with early-adopter clinics and research groups to establish case studies, generate testimonials, and accelerate adoption in the fertility market.

Cost-Effective Footprint Current revenue is modest and funding is limited, indicating a need for scalable sales motions, bundled service offerings, and pilot programs that demonstrate ROI to smaller clinics and regional networks.

Competitive Positioning As a focused fertility-immunology AI player with a compact team, Pregmune can differentiate by emphasizing rapid AI-driven insights, personalized treatment plans, and integration capabilities with existing clinic workflows.